12:00 AM
 | 
Nov 09, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

HMPL-004: Phase IIb data

Top-line data from a double-blind, international Phase IIb trial in 223 patients with active, mild to moderate UC showed that HMPL-004 met the primary endpoint of a significantly higher total clinical response rate vs. placebo at week 8 (64% vs. 44%, p=0.006). HMPL-004 also met the secondary endpoints of a significantly higher clinical remission rate (43% vs. 28%, p=0.03)...

Read the full 271 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >